ClinicaliQ Trial Snapshot
- A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice — Active Not Recruiting • Rheumatology • NCT05049798.
- This study compared how long patients stayed on guselkumab or IL-17 inhibitor treatments for psoriatic arthritis in routine clinical practice.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd). Conditions: Arthritis, Psoriatic Interventions: Guselkumab, IL-17i Lead Sponsor: Janssen Pharmaceutica N.V., Belgium Planned Enrollment: 1314 participants